IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v19y2021i5d10.1007_s40258-021-00673-1.html
   My bibliography  Save this article

Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom

Author

Listed:
  • Han Geul Byun

    (Celltrion Healthcare)

  • Minyoung Jang

    (Celltrion Healthcare)

  • Hyun Kyeong Yoo

    (Celltrion Healthcare)

  • James Potter

    (Celltrion Healthcare United Kingdom Limited)

  • Taek Sang Kwon

    (Celltrion Healthcare)

Abstract

Background CT-P13 subcutaneous (SC)—the first and only SC version of infliximab—is approved by the European Medicines Agency for the treatment of rheumatoid arthritis (RA). This new mode of infliximab administration will allow patients to self-inject at home, significantly reducing the number of outpatient visits and costs of intravenous (IV) administration. This paper describes the economic impact of introducing CT-P13 SC to the market from the UK societal perspective. Objective The budget impact analysis was conducted to assess the financial impact of the adoption of CT-P13 SC over a 5-year period. Methods A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and market share data. The analysis compared a “world with” CT-P13 SC scenario to a “world without” CT-P13 SC. A sensitivity analysis included dose escalation up to 4.1 mg/kg to reflect the real-world care delivery setting. Results Compared to the “world without” scenario, the introduction of CT-P13 SC resulted in cost savings of ₤69.3 million in the UK over a 5-year period. In the scenario analysis, the saving increased to ₤173.5 million over 5 years. Conclusion Use of CT-P13 SC may lead to substantial cost savings for the UK society.

Suggested Citation

  • Han Geul Byun & Minyoung Jang & Hyun Kyeong Yoo & James Potter & Taek Sang Kwon, 2021. "Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 735-745, September.
    • Handle: RePEc:spr:aphecp:v:19:y:2021:i:5:d:10.1007_s40258-021-00673-1
    DOI: 10.1007/s40258-021-00673-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-021-00673-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-021-00673-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kelly Stoner & Helena Harder & Lesley Fallowfield & Valerie Jenkins, 2015. "Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 8(2), pages 145-153, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Daphne Broadhurst & Marie Cooke & Deepa Sriram & Brenda Gray, 2020. "Subcutaneous hydration and medications infusions (effectiveness, safety, acceptability): A systematic review of systematic reviews," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-31, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:19:y:2021:i:5:d:10.1007_s40258-021-00673-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.